Greenwich LifeSciences
GLSI
57 hedge funds and large institutions have $39.6M invested in Greenwich LifeSciences in 2026 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 24 increasing their positions, 15 reducing their positions, and 11 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 15
0.87% less ownership
Funds ownership: 12.36% → 11.49% (-0.87%)
10% less capital inflows, than outflows
Capital inflows: $5.15M | Capital outflows: $5.72M
11% less funds holding
Funds holding: 64 → 57 (-7)
45% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.27M |
| 2 |
Jane Street
New York
|
+$674K |
| 3 |
Vanguard Portfolio Management
Malvern,
Pennsylvania
|
+$534K |
| 4 |
GSA Capital Partners
London,
United Kingdom
|
+$476K |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$436K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
-$2.13M |
| 2 |
Ancora Advisors
Cleveland,
Ohio
|
-$651K |
| 3 |
SEI Investments
Oaks,
Pennsylvania
|
-$627K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$616K |
| 5 |
EAM Investors
Solana Beach,
California
|
-$515K |
GLSI Hedge Fund Activity: Q2 2026 in Review
57 of the 8,366 institutional investors tracked by Wall St. Rank reported a position in Greenwich LifeSciences (GLSI) for Q2 2026, worth a combined $39.6M — down 3.8% from $41.1M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of GLSI and 6 opened new positions — a net loss of 5 holders — while 15 trimmed existing stakes and 24 added.
The largest buyer was BlackRock, adding an estimated $1.27M. The largest seller was Nuveen, exiting entirely with an estimated $2.13M sold.
- 57 institutional investors held Greenwich LifeSciences (GLSI) as of Q2 2026, down from 64 in Q1 2026.
- Funds reported $39.6M of Greenwich LifeSciences stock for Q2 2026, down 3.8% quarter-over-quarter.
- 6 funds opened new Greenwich LifeSciences positions in Q2 2026 and 11 closed out, a net change of -5 holders.
- The largest Greenwich LifeSciences buyer in Q2 2026 was BlackRock, an estimated $1.27M added.
- The largest Greenwich LifeSciences seller in Q2 2026 was Nuveen, an estimated $2.13M sold.
Based on aggregated 13F filings for Q2 2026.